IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Globe Newswire•13/11/2026•08:00 ET
0
Key Highlights
- ➤$105.2 million cash, expected to fund operations through the end of 2028
- ➤BOS Phase 2 trial fully enrolled; data anticipated in first quarter 2027
- ➤PH-ILD Phase 2b data anticipated in first quarter 2028
- ➤SAPH Phase 2 study planned to begin in fourth quarter 2026
- ➤Net loss $27.7 million versus $13.4 million year-earlier
Expert Statements
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases.”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
“By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions.”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
“With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”
Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026
Phase 2 data in bronchiolitis obliterans syndrome (BOS) post lung transplant anticipated in the first quarter of 2027
Get started
Create a free account to read the full story.